Clinical characteristics of patients remaining on warfarin compared with those switching to a DOAC
| . | Warfarin, N = 7772 . | DOAC switch, N = 696 . | P . |
|---|---|---|---|
| Age, mean (SD), y | 66 (16) | 67 (14) | .24 |
| Male sex, N (%) | 4003 (51) | 378 (54) | .15 |
| Weight, <50 kg, N (%) | 218 (3) | 14 (2) | .24 |
| Weight, >120 kg, N (%) | 785 (10) | 74 (11) | .68 |
| BMI >40, N (%) | 816 (11) | 74 (11) | .98 |
| Length of treatment, mean (SD), d | 470 (589) | 406 (495) | <.001 |
| Current tobacco user, N (%) | 616 (8) | 51 (7) | .57 |
| Primary indication, N (%) | |||
| DVT/PE | 3683 (47) | 179 (26) | <.001 |
| AF/flutter | 4002 (52) | 510 (73) | <.001 |
| Both | 87 (1) | 7 (1) | .78 |
| TTR, % of time (SD) | 57 (0.2) | 56 (0.2) | .89 |
| Comorbidities, N (%) | |||
| Diabetes mellitus | 1932 (25) | 153 (22) | .09 |
| Coronary artery disease | 1975 (25) | 205 (30) | .02 |
| Recent myocardial infarction, ≤6 mo | 248 (3) | 23 (3) | .87 |
| Remote myocardial infarction, >6 mo | 621 (8) | 49 (7) | .37 |
| Hypertension | 5026 (65) | 508 (73) | <.001 |
| Congestive heart failure | 1357 (18) | 136 (20) | .17 |
| Hypercoagulable state | 202 (3) | 25 (4) | .14 |
| Liver disease | 148 (2) | 15 (2) | .64 |
| Chronic kidney disease | 1009 (13) | 45 (7) | <.001 |
| Cancer | 1630 (21) | 129 (19) | .13 |
| Prior stroke or transient ischemic attack | 850 (11) | 91 (13) | .09 |
| Prior gastrointestinal bleed | 356 (5) | 22 (3) | .08 |
| Prior DVT/PE | 1197 (15) | 85 (12) | .02 |
| Any recent bleeding, ≤30 d | 150 (2) | 17 (2) | .35 |
| Any remote bleeding, >30 d | 166 (2) | 7 (1) | .04 |
| Bleeding diathesis | 54 (1) | 3 (0) | .63 |
| History of embolism, not DVT/PE | 50 (1) | 6 (1) | .46 |
| Heavy alcohol or drug use | 371 (5) | 46 (7) | .03 |
| Former tobacco use | 2281 (29) | 239 (34) | .006 |
| Falls | 223 (3) | 13 (2) | .12 |
| Seizure disorder | 101 (1) | 12 (2) | .35 |
| Peripheral arterial disease | 414 (5) | 37 (5) | .99 |
| Chemotherapy | 174 (2) | 18 (3) | .56 |
| HAS-BLED, score (SD) | 2.4 (1.4) | 2.5 (1.3) | .6 |
| Modified Charlson Comorbidity Index, score (SD) | 4.3 (2.2) | 4.3 (1) | .33 |
| Antiplatelet medications, N (%) | |||
| Aspirin (any dose) | 3093 (40) | 311 (45) | .01 |
| NSAIDs | 327 (4) | 35 (5) | .3 |
| Clopidogrel, ticlopidine | 411 (5) | 47 (7) | .1 |
| Prasugrel, ticagrelor or other antiplatelet | 25 (0.3) | 2 (0.3) | .88 |
| One antiplatelet agent | 2927 (38) | 294 (42) | .02 |
| >1 antiplatelet agent | 307 (4) | 34 (5) | .23 |
| . | Warfarin, N = 7772 . | DOAC switch, N = 696 . | P . |
|---|---|---|---|
| Age, mean (SD), y | 66 (16) | 67 (14) | .24 |
| Male sex, N (%) | 4003 (51) | 378 (54) | .15 |
| Weight, <50 kg, N (%) | 218 (3) | 14 (2) | .24 |
| Weight, >120 kg, N (%) | 785 (10) | 74 (11) | .68 |
| BMI >40, N (%) | 816 (11) | 74 (11) | .98 |
| Length of treatment, mean (SD), d | 470 (589) | 406 (495) | <.001 |
| Current tobacco user, N (%) | 616 (8) | 51 (7) | .57 |
| Primary indication, N (%) | |||
| DVT/PE | 3683 (47) | 179 (26) | <.001 |
| AF/flutter | 4002 (52) | 510 (73) | <.001 |
| Both | 87 (1) | 7 (1) | .78 |
| TTR, % of time (SD) | 57 (0.2) | 56 (0.2) | .89 |
| Comorbidities, N (%) | |||
| Diabetes mellitus | 1932 (25) | 153 (22) | .09 |
| Coronary artery disease | 1975 (25) | 205 (30) | .02 |
| Recent myocardial infarction, ≤6 mo | 248 (3) | 23 (3) | .87 |
| Remote myocardial infarction, >6 mo | 621 (8) | 49 (7) | .37 |
| Hypertension | 5026 (65) | 508 (73) | <.001 |
| Congestive heart failure | 1357 (18) | 136 (20) | .17 |
| Hypercoagulable state | 202 (3) | 25 (4) | .14 |
| Liver disease | 148 (2) | 15 (2) | .64 |
| Chronic kidney disease | 1009 (13) | 45 (7) | <.001 |
| Cancer | 1630 (21) | 129 (19) | .13 |
| Prior stroke or transient ischemic attack | 850 (11) | 91 (13) | .09 |
| Prior gastrointestinal bleed | 356 (5) | 22 (3) | .08 |
| Prior DVT/PE | 1197 (15) | 85 (12) | .02 |
| Any recent bleeding, ≤30 d | 150 (2) | 17 (2) | .35 |
| Any remote bleeding, >30 d | 166 (2) | 7 (1) | .04 |
| Bleeding diathesis | 54 (1) | 3 (0) | .63 |
| History of embolism, not DVT/PE | 50 (1) | 6 (1) | .46 |
| Heavy alcohol or drug use | 371 (5) | 46 (7) | .03 |
| Former tobacco use | 2281 (29) | 239 (34) | .006 |
| Falls | 223 (3) | 13 (2) | .12 |
| Seizure disorder | 101 (1) | 12 (2) | .35 |
| Peripheral arterial disease | 414 (5) | 37 (5) | .99 |
| Chemotherapy | 174 (2) | 18 (3) | .56 |
| HAS-BLED, score (SD) | 2.4 (1.4) | 2.5 (1.3) | .6 |
| Modified Charlson Comorbidity Index, score (SD) | 4.3 (2.2) | 4.3 (1) | .33 |
| Antiplatelet medications, N (%) | |||
| Aspirin (any dose) | 3093 (40) | 311 (45) | .01 |
| NSAIDs | 327 (4) | 35 (5) | .3 |
| Clopidogrel, ticlopidine | 411 (5) | 47 (7) | .1 |
| Prasugrel, ticagrelor or other antiplatelet | 25 (0.3) | 2 (0.3) | .88 |
| One antiplatelet agent | 2927 (38) | 294 (42) | .02 |
| >1 antiplatelet agent | 307 (4) | 34 (5) | .23 |
DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.